2.88
1.03%
-0.03
Aquestive Therapeutics Inc stock is currently priced at $2.88, with a 24-hour trading volume of 2.84M.
It has seen a -1.03% decreased in the last 24 hours and a -14.29% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.96 pivot point. If it approaches the $2.84 support level, significant changes may occur.
Previous Close:
$2.91
Open:
$2.95
24h Volume:
2.84M
Market Cap:
$262.19M
Revenue:
$50.58M
Net Income/Loss:
$-7.87M
P/E Ratio:
-6.40
EPS:
-0.45
Net Cash Flow:
$-7.38M
1W Performance:
-5.88%
1M Performance:
-14.29%
6M Performance:
+28.00%
1Y Performance:
+24.68%
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908 941 1900
Address
30 Technology Drive, Warren, NJ
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
Apr-22-19 | Initiated | H.C. Wainwright | Buy |
Jan-03-19 | Initiated | Lake Street | Buy |
Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Significant Increase in Short Interest - MarketBeat
MarketBeat
Jump Financial LLC Makes New $60000 Investment in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Defense World
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic ... - GlobeNewswire
GlobeNewswire
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic ... - Yahoo Finance
Yahoo Finance
Aquestive Therapeutics (AQST) Gains But Lags Market: What You Should Know - Yahoo Movies Canada
Yahoo Movies Canada
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - br.ADVFN.com
br.ADVFN.com
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Aquestive Therapeutics Inc (AQST) Revenue 2024
AQST reported a revenue (TTM) of $50.58 million for the quarter ending December 31, 2023, a +6.09% rise year-over-year.
Aquestive Therapeutics Inc (AQST) Net Income 2024
AQST net income (TTM) was -$7.87 million for the quarter ending December 31, 2023, a +85.54% increase year-over-year.
Aquestive Therapeutics Inc (AQST) Cash Flow 2024
AQST recorded a free cash flow (TTM) of -$7.38 million for the quarter ending December 31, 2023, a +40.25% increase year-over-year.
Aquestive Therapeutics Inc (AQST) Earnings per Share 2024
AQST earnings per share (TTM) was -$0.1541 for the quarter ending December 31, 2023, a +86.48% growth year-over-year.
Aquestive Therapeutics Inc Stock (AQST) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Schobel Alexander Mark | Chief Innovation/Tech Officer |
Mar 08 '24 |
Sale |
5.19 |
25,000 |
129,685 |
1,040,371 |
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Cap:
|
Volume (24h):